SCHEMBL3011380

SCHEMBL3011380

COc1ccc(Cl)cc1S(=O)(=O)N1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
RAB9A P51151 3/20 0.57
POLB P06746 2/20 0.57
KDM4E B2RXH2 1/20 0.57
HPGD P15428 1/20 0.57
MAPT P10636 9/20 0.56
LMNA P02545 5/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
CYP3A4 P08684 1/20 0.52
CYP2C19 P33261 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAPK1 P28482 4/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 2/20 0.50
TP53 P04637 1/20 0.50
USP2 O75604 1/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009587 0.95 POLB (0.56) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3010848 0.95 ALDH1A1 (0.54) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3016635 0.94 LMNA (0.59) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3016726 0.94 MAPT (0.59) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3009523 0.93 ALDH1A1 (0.54) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3000043 0.93 MAPT (0.54) ALDH1A1RAB9APOLBKDM4EMAPT
SCHEMBL3007942 0.93 ALDH1A1 (0.56) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3014794 0.93 CYP3A4 (0.52) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3002735 0.92 GAA (0.53) ALDH1A1RAB9APOLBKDM4EHPGD
SCHEMBL3002737 0.92 MAPT (0.56) ALDH1A1RAB9APOLBKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885RAB9A 2943/4885POLB 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.